Anti-CEA Immunoconjugates for Inaccessible Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compositions and methods for delivering antibodies and immune adjuvants are inadequate for reaching inaccessible tumors and do not provide sufficient treatment options for cancer patients.
Innovation Solution
Development of immunoconjugates comprising an anti-CEA antibody linked by conjugation to 8-Het-2-aminobenzazepine derivatives, which include a reactive functional group for covalent binding, allowing for targeted delivery to tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional antibody delivery methods are used, then treatment options are limited, but the ability to reach inaccessible tumors is insufficient
Solution Approach 1:
The patent creates immunoconjugates by chemically linking antibodies to 8-Het-2-aminobenzazepine derivatives, forming a composite structure that combines the tumor-targeting capability of antibodies with the immune-stimulating properties of the benzazepine moiety, thereby achieving both accessibility to inaccessible tumors and expanded treatment options
Solution Approach 2:
The 8-Het-2-aminobenzazepine derivative acts as an intermediary component that bridges the antibody and the immune system, enabling the delivery of immune adjuvants to tumor sites while maintaining the targeting specificity of the antibody, thus resolving the contradiction between reachability and treatment versatility
2Manufacturing precision
If immunoconjugates with reactive functional groups are used, then covalent binding capability is improved, but the complexity of conjugation increases
Solution Approach 1:
The patent modifies the chemical parameters of the 8-Het-2-aminobenzazepine derivative by incorporating specific reactive functional groups (such as maleimide, NHS ester, or azide groups) that enable selective covalent bonding to antibody residues, achieving precise manufacturing while the modular nature of these functional groups keeps the conjugation protocol manageable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoconjugates enhance tumor inhibition and stimulate immune responses, demonstrating improved efficacy in treating cancer by increasing cytokine induction and phagocytosis.
Implementation Method 1
an antibody may be covalently bound by a linker L to a 8-Het-2-aminobenzazepine (HxBz) moiety
Data Source
AI summary
The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.